| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
|
| [2] |
Wong HH,Lemoine NR, Wang Y. Oncolytic viruses for cancer therapy: overcoming the obstacles[J]. Viruses, 2010,2(1):78-106.
|
| [3] |
McDonald CJ, Erlichman C, Ingle JN, et al. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer[J]. Breast Cancer Res Treat, 2006, 99(2):177-184.
|
| [4] |
吴炅,杨犇龙. 2012 年乳腺癌研究进展回顾[J/CD]. 中华乳腺病杂志:电子版,2013,7(1):4-6.
|
| [5] |
Ribacka CS, Pesonen A, Hemminki. Cancer, stem cells, and oncolytic viruses[J]. Ann Med,2008,40(7):496-505.
|
| [6] |
Kawano H, Komaba S, Kanamori T, et al. A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy[J]. BMC Med,2007,5:28.
|
| [7] |
Miller R, Curiel DT. Towards the use of replicative adenoviral vectors for cancer gene therapy[J]. Gene Ther,1996,3(7):557-559.
|
| [8] |
Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus,in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer[J]. Nat Med, 2000, 6(8):879-885.
|
| [9] |
Garber K. China approves world's first oncolytic virus therapy for cancer treatment[J]. J Natl Cancer Inst, 2006, 98(5):298-300.
|
| [10] |
Yu W, Fang H. Clinical trials with oncolytic adenovirus in China[J]. Curr Cancer Drug Targets,2007,7(2):141-148.
|
| [11] |
Fan JK,Wei N,Ding M,et al. Targeting Gene-Virotherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene[J]. Int J Cancer,2010,127(3):707-717.
|
| [12] |
Tysome JR, Lemoine NR, Wang Y. Combination of antiangiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes[J]. Curr Opin Mol Ther, 2009,11(6):664-669.
|
| [13] |
Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy:approaches to tumor targeting and enhancing antitumor effects[J]. Semin Oncol,2005,32(6):537-548.
|
| [14] |
Hartkopf AD, Fehm T, Wallwiener D, et al. Oncolytic virotherapy of gynecologic malignancies[J]. Gynecol Oncol,2011,120(2):302-310.
|
| [15] |
Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer[J]. Nat Rev Cancer,2009,9(1):64-71.
|
| [16] |
Efferson CL, Tsuda N, Kawano K, et al. Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells[J]. J Virol,2006,80(1):383-394.
|
| [17] |
Shmulevitz M, Marcato P, Lee PW. Activated Ras signaling significantly enhances reovirus replication and spread [J].Cancer Gene Ther,2010,17(1):69-70.
|
| [18] |
Prestwich RJ, Errington F, Ilett EJ, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity[J]. Clin Cancer Res,2008,14(22):7358-7366.
|
| [19] |
Wennier ST, Liu J, McFadden G. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy[J]. Curr Pharm Biotechnol,2012,13(9):1817-1833.
|
| [20] |
Kim JH,Oh JY,Park BH,et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF[J]. Mol Ther, 2006, 14(3):361-370.
|
| [21] |
Vile R, Ando D, Kirn D. The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider[J]. Cancer Gene Ther,2002,9(12):1062-1067.
|
| [22] |
Huang TG, Savontaus MJ, Shinozaki K, et al. Telomerasedependent oncolytic adenovirus for cancer treatment[J]. Gene Ther,2003,10(15):1241-1247.
|
| [23] |
李月敏,宋三泰,江泽飞,等. 肿瘤选择性增殖腺病毒CNHK300 联合紫杉醇对HER-2 高表达乳腺癌细胞的杀伤作用[J].中国肿瘤生物治疗杂志,2006,13(2):98-102.
|
| [24] |
Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer[J]. Cancer Res,2003,63(12):3181-3188.
|
| [25] |
李月敏,宋三泰,江泽飞,等. 选择性增殖腺病毒CNHK500治疗乳腺癌的实验研究[J].中国肿瘤生物治疗杂志,2005,12(2):124-128.
|
| [26] |
Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity[J].Gene Ther,2001,8(10):746-759.
|
| [27] |
Leber MF, Bossow S, Leonard VH, et al. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism[J].Mol Ther,2011,19(6):1097-1106.
|
| [28] |
Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial[J]. Gene Ther,2000,7(10):867-874.
|
| [29] |
Markert JM, Liechty PG, Wang W, et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and posttumor resection for recurrent GBM[J]. Mol Ther, 2009, 17(1):199-207.
|
| [30] |
Todo T. “Armed” oncolytic herpes simplex viruses for brain tumor therapy[J]. Cell Adh Migr,2008,2(3):208-213.
|
| [31] |
Todo T, Martuza RL, Rabkin SD, et al. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing[J]. Proc Natl Acad Sci U S A, 2001,98(11):6396-6401.
|
| [32] |
Wang J, Hu P, Zeng M, et al. Oncolytic herpes simplex virus treatment of metastatic breast cancer[J]. Int J Oncol, 2012,40(3):757-663.
|
| [33] |
Dallas NA, Xia L, Fan F, et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition[J].Cancer Res,2009,69(5):1951-1957.
|
| [34] |
Jordan CT, Guzman ML, Noble M. Cancer stem cells[J]. N Engl J Med,2006,355(12):1253-1261.
|
| [35] |
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance[J]. Nat Rev Cancer,2005,5(4):275-284.
|
| [36] |
Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis[J]. Cancer Res, 2009, 69(8): 3382-3389.
|
| [37] |
van den Hoogen C, van der Horst G, Cheung H, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer[J]. Cancer Res,2010,70(12):5163-5173.
|
| [38] |
Zhuang X, Zhang W, Chen Y, et al. Doxorubicin-enriched,ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1[J]. BMC Cancer,2012,12:549.
|
| [39] |
Kimata H, Imai T, Kikumori T, et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus(HF10) against recurrent metastatic breast cancer[J]. Ann Surg Oncol,2006,13(8):1078-1084.
|
| [40] |
Chernichenko N, Linkov G, Li P, et al. Oncolytic vaccinia virus therapy of salivary gland carcinoma[J]. JAMA Otolaryngol Head Neck Surg,2013,139(2):173-182.
|
| [41] |
Lee SS, Eisenlohr LC, McCue PA, et al. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors[J]. Cancer Res,1994,54(13):3325-3328.
|
| [42] |
Puhlmann M,Brown CK,Gnant M,et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant[J]. Cancer Gene Ther, 2000, 7(1):66-73.
|
| [43] |
McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes[J]. Cancer Res,2001,61(24):8751-8757.
|
| [44] |
Peplinski GR, Tsung K, Meko JB, et al. Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses[J]. Ann Surg Oncol,1996,3(1):15-23.
|
| [45] |
Bleul CC, Fuhlbrigge RC, Casasnovas JM, et al. A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)[J]. J Exp Med, 1996,184(3): 1101-1109.
|
| [46] |
Gil M, Seshadri M, Komorowski MP, et al. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases[J].Proc Natl Acad Sci U S A,2013,110(14): E1291-1300.
|
| [47] |
Scholl S, Squiban P, Bizouarne N, et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2 [J]. J Biomed Biotechnol,2003,2003(3):194-201.
|
| [48] |
Norman KL,Coffey MC,Hirasawa K,et al. Reovirus oncolysis of human breast cancer[J]. Hum Gene Ther, 2002, 13(5):641-652.
|
| [49] |
朱敬之,吴志勇.呼肠孤病毒对乳腺癌细胞的治疗作用[J/CD].中华临床医师杂志:电子版,2011,5(18):5305-5309.
|
| [50] |
Ferguson MS, Lemoine NR, Wang Y. Systemic delivery of oncolytic viruses: hopes and hurdles [J]. Adv Virol, 2012,2012:805 629.
|
| [51] |
Sampath P, Li J, Hou W, et al. Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects[J]. Mol Ther,2013,21(3):620-628.
|
| [52] |
Thorne SH, Contag CH. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery [J]. Gene Ther,2008,15(10):753-758.
|
| [53] |
邱梅清,佟仲生.乳腺癌靶向药物的最新进展[J/CD]. 中华乳腺病杂志:电子版,2013,7(1):42-46.
|